Table 1.

Drug sensitivity of RMS cell lines to TRAIL, mouse anti-DR4 and anti-DR5, drozitumab (DRO), and DRO + anti-Fc antibodies

TRAIL ligandDR4 mouse mabDR5 mouse mabDRODRO + anti Fc
RMS linesSubtypeIC50 (μg/mL)Viability (%) at 0.1 μg/mLIC50 (μg/mL)Viability (%) at 1 μg/mLIC50 (μg/mL)Viability (%) at 1 μg/mLIC50 (μg/mL)Viability (%) at 1 μg/mLIC50 (μg/mL)Viability (%) at 1 μg/mL
RH4a ARMS>0.100100>1100>1100>198>180
RH18ERMS0.0044>1850.0144>1560.0145
RH28ARMS0.00114>11000.093150.659700.01817
RH30ARMS0.0017>1900.0397>1780.07915
RH36ERMS0.030450.398500.136210.986480.15615
RH41a ARMS>0.10085>190>190>198>180
RDERMS0.00329>1950.39832>1780.10834
A673EWS0.00130.076210.11240.681390.00612
CTRERMS0.01112>1850.088240.600420.00616
A204a ERMS0.07050>1100>165>1980.60845
HS729a ERMS>0.10080>1100>180>195>185
RMS13a ARMS>0.10068>145>152>192>153
MDA231BrCa0.00190.026420.02618>1690.11519
SkMDCNormal>0.10095>1100>195>1100>1100

NOTE: Dose studies of the agents on the panel of RMS cells as described in Figures 1 and 2. The percent viability was defined as the ratio between viable cells at the highest ligand or antibody dose and in the absence of ligand or antibody.

  • aRMS cell lines resistant to TRAIL ligand and drozitumab + anti-FC. MDA231, TRAIL sensitive breast cancer cell line; A673, EWS cell line, SkMDC, primary humanSkMDC.